Cyclosporine
- Generic Name
- Cyclosporine
- Brand Names
- Cequa, Gengraf, Neoral, Restasis, Sandimmune, Verkazia, Vevye, Ikervis
- Drug Type
- Small Molecule
- Chemical Formula
- C62H111N11O12
- CAS Number
- 59865-13-3
- Unique Ingredient Identifier
- 83HN0GTJ6D
- Background
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus Beauveria nivea. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novar...
- Indication
Cyclosporine is approved for a variety of conditions. Firstly, it is approved for the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants. It is also used to prevent bone marrow transplant rejection. For the above indications, cyclosporine can be used in conjunction with azathioprine and corticosteroids. Finally, cyclosporine ca...
- Associated Conditions
- Atopic Dermatitis, Bone Marrow Transplant Rejection, Chronic transplant rejection, Connective Tissue Disorders, Dry Eyes, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Immune Thrombocytopenia (ITP), Interstitial Cystitis, Juvenile Idiopathic Arthritis (JIA), Kidney Transplant Rejection, Liver Transplant Rejection, Lupus Nephritis, Nephrotic Syndrome, Ocular Rosacea, Rheumatoid Arthritis, Severe Ulcerative Colitis, Steroid Dependent Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Uveitis, Vernal Keratoconjunctivitis, Blistering disorder, Refractory Ulcerative colitis, Severe Psoriasis, Severe, active Rheumatoid arthritis, Severe, recalcitrant Plaque psoriasis, Suppressed tear production
- Associated Therapies
- -
Evaluating efficacy and safety of ocrelizumab biosimilar (Xacrel) compared to the originator
A randomized, double-blind, phase III clinical trial (Aug 2019–Oct 2021) in Iran compared Xacrel (300 mg, then 600 mg every 24 weeks) to Ocrevus (same regimen) in MS patients. Primary outcome was ARR reduction equivalence at week 48. Secondary outcomes included disability progression, relapse-free patients, MRI lesion changes, and safety assessments. The study adhered to ethical and regulatory standards.
Study Identifies Approaches to Address Patient Fears Regarding JAK Inhibitor Safety
New research led by Anthony J. Teixeira suggests JAK inhibitors are safer for dermatology patients, especially younger ones without comorbidities, with minimal long-term risks like VTE, MACE, and NMSC. Despite some side effects like acne and GI issues, JAK inhibitors may pose less risk than traditional systemic treatments for atopic dermatitis. Providers should use clear language and educational resources to address patient concerns.
Gastrointestinal Diseases Therapeutics Market to Grow by USD 18.5 Billion from 2024-2028
The Global Gastrointestinal Diseases Therapeutics Market is projected to grow by USD 18.5 billion from 2024-2028, driven by increasing disease incidence and nutritional therapies. Key players include Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, and others. High treatment costs pose a challenge.
Novaliq and Laboratoires Théa announce partnership and European Commission approval
Novaliq and Laboratoires Théa received European Commission approval for ciclosporin 0.1% eye drops (Vevizye) to treat dry eye disease (DED). Théa will commercialize Vevizye in Europe, Middle East, and North Africa. Vevizye, already FDA-approved in the US as VEVYE, targets moderate to severe DED not responsive to tear substitutes. Efficacy was demonstrated in ESSENCE-1 and ESSENCE-2 trials, with primary endpoint of total corneal fluorescein staining score at Day 29.
Company Statement on FDA Advisory Committee Meeting
FDA's GIDAC discussed Intercept's sNDA for OCALIVA for PBC treatment; Intercept disappointed by the committee's vote, emphasizing OCALIVA's clinical benefits. FDA to make final decision by October 15, 2024.
The structural basis for the collagen processing by human P3H1/CRTAP/PPIB ternary complex
Recombinant human PPIB produced from E. coli, while CRTAP and P3H1 required HEK293-based system for expression. P3H1, CRTAP, and PPIB co-expressed in Expi293F cells, purified via two-step affinity chromatography, and analyzed by cryo-EM. Model building used AlphaFold2 predictions and crystal structures, refined with Phenix and COOT. Interaction studies included CRISPR-Cas9 knockouts, collagen binding assays, and ITC analysis. 2-OG dependent oxygenase activity measured, and ICP-MS used for Fe content analysis.
Drug-Drug Interactions and the Clinical Tolerability of Colchicine Among Patients With COVID-19
Drug-drug interactions with statins and calcium channel blockers did not significantly alter colchicine's safety and efficacy in COVID-19 patients, suggesting pharmacokinetic changes do not translate into clinically significant effects.
Related Clinical Trials:
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath